Alkermes Expects Record $1B Proprietary Sales in 2025 Amid Orexin Pipeline Advancements

Alkermes anticipates record proprietary product sales of over $1 billion for 2025, driven by progress in its orexin pipeline. The company's CEO described the quarter as "very successful" with strong commercial and financial performance, and stated that Alkermes is on track to deliver on its key objectives for the year. The company is also now sustainably profitable and debt-free.

DUBLIN, July 2, 2025 — Alkermes plc (Nasdaq: ALKS) reported its financial results for the second quarter of 2025, showcasing robust performance across its proprietary products. The company generated revenues of $390.7 million, up from $399.1 million in the same period last year, and reported GAAP net income of $87.1 million, an increase from $94.7 million in the second quarter of 2024 [1].

Key financial highlights include:
- Revenues: Total revenues increased to $390.7 million, with proprietary net sales reaching $307.2 million.
- Profitability: GAAP net income from continuing operations was $87.1 million, while EBITDA from continuing operations stood at $101.6 million.
- Product Performance: Revenues for VIVITROL®, ARISTADA®, and LYBALVI® grew by 9%, 18%, and 18% respectively, compared to the second quarter of 2024.

CEO Richard Pops noted that the quarter was "very successful," highlighting strong commercial and financial performance. He also reiterated the company's 2025 financial expectations, including record proprietary product sales of over $1 billion, driven by progress in its orexin pipeline [1].

Alkermes is also now sustainably profitable and debt-free, with cash, cash equivalents, and total investments reaching $1.05 billion as of June 30, 2025, up from $916.2 million at March 31, 2025 [1].

The company will present detailed Vibrance-1 results at the upcoming World Sleep Congress and topline results from Vibrance-2 in patients with narcolepsy type 2 this fall. These studies underscore the potential of orexin 2 receptor agonists to transform the treatment of narcolepsy [1].

References:
[1] https://investor.alkermes.com/news-releases/news-release-details/alkermes-plc-reports-second-quarter-2025-financial-results